Breaking News, Collaborations & Alliances

Harbour BioMed & Kelun-Biotech License TSLP Antibody to Windward Bio

Under the terms of the agreement, Windward Bio is granted an exclusive license to research, develop, manufacture, and commercialize HBM9378/SKB378 globally.

Author Image

By: Charlie Sternberg

Associate Editor

Harbour BioMed, a global biopharmaceutical company, and Sichuan Kelun Biotech BioPharmaceutical have entered into a license agreement with Windward Bio AG for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody co-developed by Harbour BioMed and Kelun-Biotech. Under the terms of the agreement, Windward Bio is granted an exclusive license to research, develop, manufacture, and commercialize HBM9378/SKB378 globally, excluding Greater China and several Sou...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters